Laudanum his "archanum" or "laudanum", may or may not have contained opium. Paracelsus' laudanum was strikingly different from the standard laudanum of the 17th century and beyond, containing crushed pearls, musk, amber, and other substances. One researcher has documented that "Laudanum, as listed in the "London Pharmacopoeia" (1618), was a pill made from opium, saffron, castor, ambergris, musk and nutmeg". Laudanum remained largely unknown until the 1660s when English physician Thomas Sydenham (1624–1689) compounded a proprietary opium tincture that he also named laudanum, although it differed substantially from the laudanum of Paracelsus. In 1676 Sydenham published a seminal work, "Medical Observations
Personalized medicine will work based on their genome. The personal genotype can allow physicians to have more detailed information that will guide them in their decision in treatment prescriptions, which will be more cost-effective and accurate. As quoted from the article "Pharmacogenomics: The Promise of Personalised Medicine", “therapy with the right drug at the right dose in the right patient” is a description of how personalized medicine will affect the future of treatment. For instance, tamoxifen used to be a drug commonly prescribed to women with ER+ breast cancer, but 65% of women initially taking it developed resistance. After some research by